Video Experimental Relacionado
Updated: Sep 12, 2025
07:56
A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices
Published on: August 11, 2021
3.4K
Inhibidores del transporte de monoaminas vesiculares: usos actuales y direcciones futuras
Liana S Rosenthal1, Mena Farag2, N Ahmad Aziz3
1Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Lancet (London, England)
|August 9, 2025
Resumen
Los inhibidores del transportador de monoaminas vesiculares 2 (VMAT2) son vitales para el tratamiento del movimiento y los trastornos neuropsiquiátricos mediante la regulación de la liberación de neurotransmisores. La dosificación personalizada, informada por la genética, mejora la eficacia y la seguridad del inhibidor VMAT2.
Área de la Ciencia:
- La neurociencia
- Farmacología
- La genética
Sus antecedentes:
- El transportador monoamínico vesicular 2 (VMAT2) juega un papel crítico en el empaquetado de neurotransmisores en las vesículas sinápticas.
- La desregulación de VMAT2 está implicada en varios trastornos del movimiento y neuropsiquiátricos.
Objetivo del estudio:
- Revisar los avances en los inhibidores de VMAT2 para el tratamiento de afecciones neurológicas y psiquiátricas.
- Explorar el papel de VMAT2 en la neurotransmisión y sus implicaciones terapéuticas.
Principales métodos:
- Revisión de la literatura reciente sobre los inhibidores de VMAT2 y sus mecanismos.
- Análisis de la eficacia clínica en trastornos del movimiento hipercinético.
- Examen de las influencias farmacogenéticas en el metabolismo de los inhibidores de VMAT2.
Principales resultados:
- Los inhibidores de VMAT2 como la tetrabenazina, la deutetrabenazina y la valbenazina son efectivos en el tratamiento de la enfermedad de Huntington, la discinesia tardía y el síndrome de Tourette.
- Los inhibidores modulan el almacenamiento y la liberación de neurotransmisores, reduciendo la actividad sináptica excesiva.
- Las variaciones genéticas afectan el metabolismo del inhibidor VMAT2, lo que requiere una dosificación personalizada.
Conclusiones:
- Los inhibidores de VMAT2 ofrecen beneficios terapéuticos significativos para el movimiento y los trastornos neuropsiquiátricos.
- La farmacogenética puede optimizar los resultados del tratamiento a través de la medicina de precisión.
- La investigación adicional sobre la inhibición de VMAT2 puede ampliar las aplicaciones terapéuticas para afecciones neurológicas y psiquiátricas.
Más Videos Relacionados
Videos de Conceptos Relacionados
01:23Antidepressant Drugs: MAOIs and Other Agents
349
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
349
01:21Drugs Affecting Neurotransmitter Release or Uptake
1.2K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.2K
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
880
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
880
01:26Cholinergic Antagonists: Therapeutic Uses
873
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
873
01:25Adrenergic Agonists: Indirect-Acting Agents
1.8K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.8K
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
615
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
615